Study design, rationale, and baseline characteristics of ATTAIN-HYPERTENSION, a phase 3 trial of the oral GLP-1 receptor agonist orforglipron for hypertension
Luke Joseph Laffin, Markus Peter Schlaich, Michael E. Hall, Cathy C. Xie et autres
ABSTRACT Background Up to three-quarters of primary hypertension is epidemiologically attributed to excess adiposity. Incretin-based therapies are consistently associated with reduced blood pressure (BP) in clinical trials; however, no prior trial has investigated incretin-based therapies for hypertension treatment with BP as its …
us, au (code pays fourni par la source)
0 citations
American Journal of Preventive Cardiology